Получить поддержку менеджера

Teaching English Online – The Considerations You Must Make – Online Education

If the Advisory Committee does not make a recommendation with respect to the use of a vaccine at the Advisory Committee’s first regularly scheduled meeting after the licensure of the vaccine or any new indication for chaterba the vaccine, the Advisory Committee shall provide an update on the status of such committee’s review. Upon the licensure of any vaccine or any new indication for a vaccine, the Advisory Committee on Immunization Practices (in this section referred to as the Advisory Committee) shall, as appropriate, consider the use of the vaccine at its next regularly scheduled meeting. To support the purposes described in paragraph (2), the Secretary, acting through the Director of BARDA, may enter into an agreement (including through the use of grants, huge cock.com contracts, cooperative agreements, or live cam erotic other transactions as described in paragraph (5)) with an independent, nonprofit entity to- (I)foster and accelerate the development and innovation of medical countermeasures and technologies that may assist advanced research and the development of qualified countermeasures and qualified pandemic or epidemic products, including through the use of strategic venture capital practices and methods; (II)promote the development of new and promising technologies that address urgent medical countermeasure needs, as identified by the Secretary; (III)address unmet public health needs that are directly related to medical countermeasure requirements, such as novel antimicrobials for multidrug resistant organisms and multiuse platform technologies for diagnostics, prophylaxis, vaccines, and therapeutics; and (IV)provide expert consultation and advice to foster viable medical countermeasure innovators, including helping qualified countermeasure innovators navigate unique industry challenges with respect to developing chemical, biological, radiological, and nuclear countermeasure products.

300hh-10(b)(7)) is amended- (1)in the matter preceding subparagraph (A), by striking the first sentence and inserting Develop, and update not later than March 1 of each year, a coordinated 5-year budget plan based on the medical countermeasure priorities described in subsection (d), including with respect to chemical, biological, radiological, and nuclear agent or agents that may present a threat to the Nation, including such agents that are novel or emerging infectious diseases, and the corresponding efforts to develop qualified countermeasures (as defined in section 319F-1), security countermeasures (as defined in section 319F-2), and qualified pandemic or epidemic products (as defined in section 319F-3) for each such threat.; (2)in subparagraph (C), by striking ; and and inserting a semicolon; (3)in subparagraph (D), by striking to the appropriate committees of Congress upon request. Not later than 18 months after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention shall submit to the appropriate committees of the Congress, and make publicly available, a report on the results of the review under subsection (a), including any recommendations on improving the consistency of the processes described in such subsection. Such report shall include recommendations with respect to any agreement or activities carried out pursuant to this subparagraph.

The report described in paragraph (1) shall review the current status of vaccine development and, as appropriate- (A)consider the optimal process to determine which vaccines would be beneficial to public health and how information on such vaccines is disseminated to key stakeholders; (B)examine and identify whether obstacles exist that inhibit the development of beneficial vaccines; and (C)make recommendations about how best to remove any obstacles identified under subparagraph (B) in order to promote and incentivize vaccine innovation and development. Secretary shall place a high value on the demonstrated experience of the entity in partnering with the Federal Government to meet identified strategic needs. In preparing the report under this subsection, the Secretary may consult with- (A)representatives of relevant Federal agencies and departments, including the Department of Defense and the Department of Veterans Affairs; (B)academic researchers; (C)developers and manufacturers of vaccines; (D)medical and public health practitioners; (E)representatives of patient, policy, and advocacy organizations; and (F)representatives of other entities, as the Secretary determines appropriate. The Secretary shall award a priority review voucher to the sponsor of a material threat medical countermeasure application upon approval by the Secretary of such material threat medical countermeasure application.

Any waiver under this subsection shall take effect on the date on which the Secretary posts information on the Internet website as provided for in this subsection. The sponsor of a material threat medical countermeasure application that receives a priority review voucher under this section may transfer (including by sale) the entitlement to such voucher to a sponsor of a human drug for which an application under section 505(b)(1) or section 351(a) of the Public Health Service Act will be submitted after the date of the approval of the material threat medical countermeasure application. An initiative subject to a waiver under paragraph (1) that is ongoing after the date on which the waiver expires, shall be subject to the requirements of subchapter I of chapter 35 of title 44, United States Code, and the Secretary shall ensure that compliance with such requirements occurs in as timely a manner as possible based on the applicable circumstances, but not to exceed 30 calendar days after the expiration of the applicable waiver..

Авторизация
*
*
Регистрация
*
*
*
*
Генерация пароля